vs
阿普塔集团（ATR）与Healthpeak Properties（DOC）财务数据对比。点击上方公司名可切换其他公司
阿普塔集团的季度营收约是Healthpeak Properties的1.3倍（$962.7M vs $719.4M），Healthpeak Properties净利率更高（73.2% vs 7.7%，领先65.5%），阿普塔集团同比增速更快（13.5% vs 3.1%），Healthpeak Properties自由现金流更多（$357.0M vs $96.9M），过去两年Healthpeak Properties的营收复合增速更高（8.9% vs 2.6%）
阿普塔集团（AptarGroup, Inc.）是总部位于美国的全球性制造企业，主营消费品分配包装产品及药物给药装置的研发与生产，目前在全球18个国家设有生产运营基地，服务医药、快消等多领域客户。
Healthpeak Properties是美国医疗地产领域的房地产投资信托基金，核心投资范畴覆盖老年住宅、生命科学相关物业及医疗办公楼三类资产。公司2007年于马里兰州组建，总部设在科罗拉多州丹佛市，在尔湾、纳什维尔、旧金山均设有办事处，截至2019年12月31日共持有617处物业的权益。
ATR vs DOC — 直观对比
营收规模更大
ATR
是对方的1.3倍
$719.4M
营收增速更快
ATR
高出10.5%
3.1%
净利率更高
DOC
高出65.5%
7.7%
自由现金流更多
DOC
多$260.1M
$96.9M
两年增速更快
DOC
近两年复合增速
2.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $962.7M | $719.4M |
| 净利润 | $74.3M | $114.0M |
| 毛利率 | — | — |
| 营业利润率 | 11.0% | 17.4% |
| 净利率 | 7.7% | 73.2% |
| 营收同比 | 13.5% | 3.1% |
| 净利润同比 | -26.4% | 2406.4% |
| 每股收益（稀释后） | $1.13 | $0.16 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ATRDOC
| Q4 25 | $962.7M | $719.4M | ||
| Q3 25 | $961.1M | $705.9M | ||
| Q2 25 | $966.0M | $694.3M | ||
| Q1 25 | $887.3M | $702.9M | ||
| Q4 24 | $848.1M | $698.0M | ||
| Q3 24 | $909.3M | $700.4M | ||
| Q2 24 | $910.1M | $695.5M | ||
| Q1 24 | $915.4M | $606.6M |
净利润ATRDOC
| Q4 25 | $74.3M | $114.0M | ||
| Q3 25 | $127.9M | $-117.1M | ||
| Q2 25 | $111.7M | $31.7M | ||
| Q1 25 | $78.8M | $42.8M | ||
| Q4 24 | $100.9M | $4.5M | ||
| Q3 24 | $100.0M | $85.9M | ||
| Q2 24 | $90.5M | $146.0M | ||
| Q1 24 | $83.1M | $6.7M |
毛利率ATRDOC
| Q4 25 | — | — | ||
| Q3 25 | — | 58.6% | ||
| Q2 25 | — | 60.2% | ||
| Q1 25 | — | 61.1% | ||
| Q4 24 | — | 60.3% | ||
| Q3 24 | — | 60.0% | ||
| Q2 24 | — | 60.6% | ||
| Q1 24 | — | 59.8% |
营业利润率ATRDOC
| Q4 25 | 11.0% | 17.4% | ||
| Q3 25 | 14.2% | 9.2% | ||
| Q2 25 | 14.9% | 5.7% | ||
| Q1 25 | 12.8% | 7.7% | ||
| Q4 24 | 14.2% | -2.2% | ||
| Q3 24 | 15.2% | 14.1% | ||
| Q2 24 | 13.8% | 22.3% | ||
| Q1 24 | 12.2% | 3.7% |
净利率ATRDOC
| Q4 25 | 7.7% | 73.2% | ||
| Q3 25 | 13.3% | -16.6% | ||
| Q2 25 | 11.6% | 4.6% | ||
| Q1 25 | 8.9% | 6.1% | ||
| Q4 24 | 11.9% | 0.7% | ||
| Q3 24 | 11.0% | 12.3% | ||
| Q2 24 | 9.9% | 21.0% | ||
| Q1 24 | 9.1% | 1.1% |
每股收益（稀释后）ATRDOC
| Q4 25 | $1.13 | $0.16 | ||
| Q3 25 | $1.92 | $-0.17 | ||
| Q2 25 | $1.67 | $0.05 | ||
| Q1 25 | $1.17 | $0.06 | ||
| Q4 24 | $1.48 | $0.02 | ||
| Q3 24 | $1.48 | $0.12 | ||
| Q2 24 | $1.34 | $0.21 | ||
| Q1 24 | $1.23 | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $409.5M | $467.5M |
| 总债务越低越好 | $1.1B | $9.8B |
| 股东权益账面价值 | $2.7B | $7.5B |
| 总资产 | $5.3B | $20.3B |
| 负债/权益比越低杠杆越低 | 0.43× | 1.31× |
8季度趋势，按日历期对齐
现金及短期投资ATRDOC
| Q4 25 | $409.5M | $467.5M | ||
| Q3 25 | $264.8M | $91.0M | ||
| Q2 25 | $169.8M | $89.4M | ||
| Q1 25 | $136.8M | $70.6M | ||
| Q4 24 | $226.2M | $119.8M | ||
| Q3 24 | $327.9M | $180.4M | ||
| Q2 24 | $223.9M | $106.9M | ||
| Q1 24 | $201.1M | $101.8M |
总债务ATRDOC
| Q4 25 | $1.1B | $9.8B | ||
| Q3 25 | $546.0M | $9.1B | ||
| Q2 25 | $535.1M | $9.0B | ||
| Q1 25 | $561.2M | $8.9B | ||
| Q4 24 | $688.1M | $8.7B | ||
| Q3 24 | $822.7M | $8.6B | ||
| Q2 24 | $681.5M | $8.6B | ||
| Q1 24 | $680.4M | $8.8B |
股东权益ATRDOC
| Q4 25 | $2.7B | $7.5B | ||
| Q3 25 | $2.8B | $7.6B | ||
| Q2 25 | $2.7B | $7.9B | ||
| Q1 25 | $2.5B | $8.2B | ||
| Q4 24 | $2.5B | $8.4B | ||
| Q3 24 | $2.5B | $8.6B | ||
| Q2 24 | $2.4B | $8.8B | ||
| Q1 24 | $2.3B | $8.9B |
总资产ATRDOC
| Q4 25 | $5.3B | $20.3B | ||
| Q3 25 | $5.1B | $19.6B | ||
| Q2 25 | $4.9B | $19.8B | ||
| Q1 25 | $4.5B | $19.8B | ||
| Q4 24 | $4.4B | $19.9B | ||
| Q3 24 | $4.6B | $20.0B | ||
| Q2 24 | $4.5B | $20.2B | ||
| Q1 24 | $4.4B | $20.5B |
负债/权益比ATRDOC
| Q4 25 | 0.43× | 1.31× | ||
| Q3 25 | 0.20× | 1.20× | ||
| Q2 25 | 0.20× | 1.14× | ||
| Q1 25 | 0.22× | 1.08× | ||
| Q4 24 | 0.28× | 1.04× | ||
| Q3 24 | 0.32× | 1.00× | ||
| Q2 24 | 0.28× | 0.98× | ||
| Q1 24 | 0.29× | 0.99× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $183.7M | $1.3B |
| 自由现金流经营现金流 - 资本支出 | $96.9M | $357.0M |
| 自由现金流率自由现金流/营收 | 10.1% | 49.6% |
| 资本支出强度资本支出/营收 | 9.0% | 124.4% |
| 现金转化率经营现金流/净利润 | 2.47× | 10.99× |
| 过去12个月自由现金流最近4个季度 | $299.6M | — |
8季度趋势，按日历期对齐
经营现金流ATRDOC
| Q4 25 | $183.7M | $1.3B | ||
| Q3 25 | $177.6M | $315.0M | ||
| Q2 25 | $126.0M | $363.5M | ||
| Q1 25 | $82.7M | $279.4M | ||
| Q4 24 | $178.2M | $1.1B | ||
| Q3 24 | $229.3M | $318.2M | ||
| Q2 24 | $143.6M | $316.2M | ||
| Q1 24 | $92.3M | $152.6M |
自由现金流ATRDOC
| Q4 25 | $96.9M | $357.0M | ||
| Q3 25 | $114.3M | — | ||
| Q2 25 | $62.5M | — | ||
| Q1 25 | $25.9M | — | ||
| Q4 24 | $112.2M | $333.7M | ||
| Q3 24 | $162.7M | — | ||
| Q2 24 | $75.4M | — | ||
| Q1 24 | $16.7M | — |
自由现金流率ATRDOC
| Q4 25 | 10.1% | 49.6% | ||
| Q3 25 | 11.9% | — | ||
| Q2 25 | 6.5% | — | ||
| Q1 25 | 2.9% | — | ||
| Q4 24 | 13.2% | 47.8% | ||
| Q3 24 | 17.9% | — | ||
| Q2 24 | 8.3% | — | ||
| Q1 24 | 1.8% | — |
资本支出强度ATRDOC
| Q4 25 | 9.0% | 124.4% | ||
| Q3 25 | 6.6% | — | ||
| Q2 25 | 6.6% | — | ||
| Q1 25 | 6.4% | — | ||
| Q4 24 | 7.8% | 105.6% | ||
| Q3 24 | 7.3% | — | ||
| Q2 24 | 7.5% | — | ||
| Q1 24 | 8.3% | — |
现金转化率ATRDOC
| Q4 25 | 2.47× | 10.99× | ||
| Q3 25 | 1.39× | — | ||
| Q2 25 | 1.13× | 11.48× | ||
| Q1 25 | 1.05× | 6.52× | ||
| Q4 24 | 1.77× | 235.43× | ||
| Q3 24 | 2.29× | 3.71× | ||
| Q2 24 | 1.59× | 2.17× | ||
| Q1 24 | 1.11× | 22.85× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ATR
| Pharma Segment | $833.1M | 87% |
| Other | $129.6M | 13% |
DOC
暂无分部数据
